Investors Buy Large Volume of Call Options on Vera Therapeutics (NASDAQ:VERA)

Vera Therapeutics, Inc. (NASDAQ:VERA) was the target of unusually large options trading on Tuesday. Stock investors purchased 3,132 call options on the company. This represents an increase of 105% compared to the typical daily volume of 1,526 call options.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $31.77 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The company has a market cap of $2.29 billion, a PE ratio of -5.42 and a beta of 0.96. The firm has a fifty day moving average price of $34.59 and a two-hundred day moving average price of $36.96. Vera Therapeutics has a fifty-two week low of $23.05 and a fifty-two week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the prior year, the company posted ($1.20) earnings per share. Analysts expect that Vera Therapeutics will post -6.44 EPS for the current year.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Strong ORIGIN 3 efficacy results: In the final 104-week analysis of 428 patients with IgA nephropathy, TRUTAKNA stabilized kidney function, with an annualized eGFR decline of 0.6 mL/min/1.73m² versus 5.6 for placebo. The treatment also reduced the risk of a composite kidney disease progression event by 76%, with a hazard ratio of 0.24. ORIGIN 3: Atacicept Reduces Kidney Function Decline in IgAN
• Positive Sentiment: Regulatory pathway strengthened: Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026 seeking full FDA approval, potentially expanding TRUTAKNA beyond its current accelerated approval based on proteinuria reduction. Vera’s TRUTAKNA Shows Two-Year Kidney Protection
• Positive Sentiment: Commercial launch momentum: Vera reported more than 350 patient start forms during TRUTAKNA’s first 10 weeks, along with paid claims and encouraging early payer policies. Safety was generally comparable to placebo, supporting the product’s potential market adoption. Vera’s Trutakna Shows Two-Year Kidney Protection
• Neutral Sentiment: Competitive implications: The data intensify competition in the IgA nephropathy market and could improve Vera’s positioning, but investors may await detailed conference results and additional evidence supporting long-term disease modification. Vera’s Strong Phase 3 IgAN Data Intensify Rivalry
• Negative Sentiment: Profit-taking and remaining risks: Shares initially rallied on the trial win but later reversed and decreased amid heightened volatility. TRUTAKNA remains under accelerated approval, so continued approval depends on confirmation of clinical benefit. Immunosuppression, infections and injection-site reactions, as well as uncertainty over payer uptake and full FDA approval, remain risks.

Wall Street Analysts Forecast Growth

A number of analysts have commented on VERA shares. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vera Therapeutics in a research note on Tuesday. Needham & Company LLC set a $125.00 price objective on shares of Vera Therapeutics in a research note on Wednesday, July 8th. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday. JPMorgan Chase & Co. upped their price target on Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 8th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.15.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $35.12, for a total transaction of $649,720.00. Following the sale, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $8,261,769.28. The trade was a 7.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,250 shares of company stock worth $3,307,800 over the last quarter. 15.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Optimize Financial Inc boosted its stake in shares of Vera Therapeutics by 1.5% during the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after acquiring an additional 256 shares during the period. Intech Investment Management LLC raised its holdings in Vera Therapeutics by 2.4% in the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after acquiring an additional 424 shares during the period. Arizona State Retirement System grew its position in shares of Vera Therapeutics by 12.3% in the second quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock valued at $507,000 after purchasing an additional 1,295 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Vera Therapeutics by 8.8% during the first quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock worth $645,000 after buying an additional 1,300 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Vera Therapeutics by 16.8% in the fourth quarter. ProShare Advisors LLC now owns 12,938 shares of the company’s stock valued at $655,000 after acquiring an additional 1,864 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.